EMA Withdrawn: Gavreto (pralsetinib) — Blueprint Medicines (Netherlands) B.V.

View source ↗

Summary

The EMA has withdrawn Gavreto (pralsetinib) from its marketing authorization; the decision was made on 17 July 2024 and relates to a previously conditional appr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• GAVRETO (pralsetinib)

Snippet

Status: Withdrawn. Therapeutic area: Carcinoma, Non-Small-Cell Lung. MAH: Blueprint Medicines (Netherlands) B.V.. Decision date: 17/07/2024. Conditional approval